Daphne’s body tells the story of just how much she has endured. After living in horrific conditions surrounded by rubbish and ...

Jordan Routch had never heard of Friedreich’s ataxia, but he’s running the Buffalo Creek half marathon to raise awareness ...

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced ...

Researchers have identified covert deletions of the proximal FXN gene that standard testing mistakes for identical repeat ...

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded ...

The pair started competing in powerlifting roughly five years before now, according to The Virginian-Pilot. Both deal with muscle incoordination and slurred speech as part of their respective ...

A year-long Dutch study shows the PROM-Ataxia questionnaire validly captures disease burden in spinocerebellar ataxia, even ...

A monthly snapshot of FDA activity involving therapies used in the prevention, diagnosis, and treatment of neurologic conditions.

Shionogi will acquire IntraBio for $2 billion upfront, adding AQNEURSA for rare neurological diseases. See what the deal means for its portfolio. Read more.

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on October 5, 2026, ...

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a ...

Steve Alexy and Arlyn Smith are a Franklin couple who have each overcome physical disabilities to become successful ...